Dr Caroline Johnson

Dr Caroline Johnson

Conservative — Sleaford and North Hykeham

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

It is a pleasure to serve under your chairmanship, Sir John. I congratulate my right hon. Friend the Member for Tatton (Esther McVey) and the hon. Member for Blackley and Middleton South (Graham Stringer) on securing this important debate. I need to declare some interests: I am an NHS consultant paediatrician and a member of the Royal College of Paediatrics and Child Health and of the British Medical Association, and I worked as a volunteer vaccinator in the covid scheme for much of the pandemic. The Medicines and Healthcare Products Regulatory Agency is there to ensure that our medicines are safe and effective. It is an important organisation, but it is also an executive agency of the Department of Health and Social Care and, ultimately, Government Ministers are responsible for what goes on. As we have heard, numerous concerns have been raised. I will make a couple of general comments and then review a couple of specific cases. First, the yellow card scheme is important for safety monitoring. Awareness of the scheme has increased since the pandemic; reports went up 75% between 2020 and 2022. Can the Minister confirm that the MHRA has the resources to manage that increase in reports and is able to look at them effectively to make sure that nothing is missed? Many hon. Members mentioned the vaccine damage payment. People left severely disabled by an adverse reaction to a vaccine may be able to claim through the scheme. Since 2022, £32 million has been paid out in compensation, with £83 million in administration costs. Is the Minister on top of those costs? Is he happy that the costs are proportional to the administration being provided? The Government have repeatedly said that they are assessing options to improve the scheme. Can the Minister enlighten us on what those options are and when the Government plan to make a decision? My confidence in the MHRA was eroded further following a debate in May 2025 on what should have been a very straightforward statutory instrument, which set the agency’s fees. When looking at the sums, a civil service pay rise of 2.2% was assumed, which was below inflation; the Minister could not tell us whether it was the intention of the Government to provide a below-inflation pay rise, which in the end they did not. The agency failed to add the Government’s own rise in national insurance, and the Minister could not tell us whether or not it needed to be applied, which it did. That left the agency about 15% out in its sums. Given that it works on a cost recovery basis, the Minister insisted that it could manage—but, if that were the case, why was it asking for more money than it needed? In practice, it did not have enough, because it came back for more money just months later. The Minister needs to ensure that he has a grip not just on what the agency is doing medically, but on whether its sums are right, because ultimately it is important for all of us to get good medication. Moving on to specific cases, I want to look at the puberty blockers trial. One of the key roles of the MHRA is in regulating and approving clinical trials. The puberty blockers trial will include 226 children—226 physically healthy children, who are developing normally from a pubertal point of view. They are going to be given powerful drugs that could cause them potentially serious damage. The trial has been discussed in detail on the Floor of the House, but I want to look specifically at the MHRA’s role. After the trial was approved, Professor Jacob George was appointed as the chief medical and scientific officer of the MHRA in January. In February, a redacted letter was produced, talking about concerns related to the wellbeing of participants. At first, the Government appeared not to heed that warning. The following month, Professor George recused himself from further discussion. It was not clear why, but it led to concerns in the press that it was due to his gender-critical views, which are, of course, protected views under the Equality Act 2010. Could the Minister shed further light on what happened? In June, it was decided that a minimum age would be set of 11 for girls and 12 for boys. Some people asked me, “Why are those different?”. The ages are different because girls go into puberty earlier than boys—an ironic recognition of biology in a trial that otherwise believes that girls may be able to be boys. However, the MHRA recommended a minimum age of 14. Could the Minister explain why there is a difference? The MHRA said that the minimum age was there to strengthen safeguards and ensure the monitoring of safety, bone health and cognition. Why have the Government chosen to have a minimum age of 11 or 12—in some cases, primary school children—rather than 14? I appreciate the Minister has been in the role for only a few months, but is he content to be responsible for the trial? Is he—as the previous Secretary of State said they would—receiving monthly updates on the trial’s progress? I want to ask about the Hughes Report, published in February 2024. Members are familiar with the details of this scandal. We do not have exact numbers, but we know that around 10,000 women were affected by pelvic mesh and around 20,000 children were born disabled after exposure to sodium valproate in the womb. Earlier this month, a documentary called “Mums v Big Pharma” focused on Janet and Emma, two mums to children affected by intrauterine exposure to sodium valproate. I was fortunate to meet Janet and Emma recently to hear about their campaign. They did not know that these drugs were going to harm their children, but they have evidence that shows the Government knew that it might. They are inspiring women, and I pay tribute to them and their campaign. It is now approaching three years since this report, and what have the Government done? As far as I can see, nothing. The last Labour Prime Minister failed to act; the latest Labour Prime Minister raised hopes with his words, but has so far dashed them with his lack of action. Last month, the Minister for Patient Safety said “a decision has not yet been taken to provide financial redress,”—[Official Report, 29 October 2026; Vol. 792, c. 552.] so when will the Government respond to the Hughes Report and when will that decision be made? That Minister also said that the foetal exposure to medicines pilot service in hospitals in Manchester and Newcastle will be extended. These are run by NHS England, which the Government are abolishing. Will this extension still happen? If so, can the Minister confirm who will be responsible for it? In summary, there are concerns about the MHRA’s ability to respond to concerns raised, to act quickly, to improve medicines and to manage the financial adding-up. The Minister has only been in post for a few months, but he is a clever man and I know he is concerned to do well; I am sure he has identified the problems, but will he act? This Government have a tendency to kick the can down the road. There is no workforce plan and there are endless delays to plans for maternity. I know you, Sir John, are particularly interested in the acquired brain injury plan; that has also been further delayed, having been promised for last December. Warm words are cold comfort when they do not come with action. Can the Minister reassure the House that he—as a new Minister, whom I welcome to his position and am glad to see there—will act promptly?

More from Dr Caroline Johnson

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Dr Caroline Johnson's full parliamentary record including voting history, expenses and all other contributions, see the Dr Caroline Johnson report card.